- Home
- BALY vs SGMT Comparison
BALY vs SGMT Comparison
Compare BALY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BALY | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | 11700 | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.1M | 761.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BALY | SGMT |
|---|---|---|
| Price | $13.51 | $9.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $9.67 | ★ $27.91 |
| AVG Volume (30 Days) | 76.1K | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,436,189,000.00 | $2,000,000.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.44 | $4.50 |
| 52 Week High | $19.60 | $11.45 |
Technical Indicators
Market Signals| Indicator | BALY | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 53.26 |
| Support Level | $13.38 | $6.44 |
| Resistance Level | $14.20 | $11.33 |
| Average True Range (ATR) | 0.57 | 0.65 |
| MACD | -0.13 | 0.20 |
| Stochastic Oscillator | 52.04 | 70.96 |
Price Performance
Historical ComparisonAbout BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.